This is probably a repost, but cool anyways.

CSHL Professor Lloyd Trotman and his team have discovered that menadione kills prostate cancer cells in mice by depleting a lipid known as PIP. Their findings set the stage for pilot studies in human prostate cancer patients and point to a potential treatment target for myotubular myopathy, a rare and fatal disease diagnosed in infant boys.

Prostate cancer is a quiet killer. In most men, it’s treatable. However, in some cases, it resists all known therapies and turns extremely deadly. A new discovery at Cold Spring Harbor Laboratory (CSHL) points to a potentially groundbreaking solution. CSHL Professor Lloyd Trotman’s lab has found that the pro-oxidant supplement menadione slows prostate cancer progression in mice. The supplement is a precursor to vitamin K, commonly found in leafy greens. The story begins more than two decades ago.

From the press release.

Cyclarity Therapeutics is pleased to announce regulatory approval to begin its first-in-human clinical trial. The trial will be conducted at CMAX, one of Australia’s leading clinical research centers, in partnership with Monash University. This effort will be led by Dr. Stephen Nicholls of the Victorian Heart Institute (VHI), a distinguished leader in cardiovascular medicine. In addition to a traditional SAD/MAD phase 1 trial, the authorization includes an allowance to enroll 12 patients with Acute Coronary Syndrome (ACS) to assess the safety of UDP-003 in individuals with plaque buildup, as well as to explore anecdotal evidence of efficacy. This represents a critical first step in evaluating the potential impact of our therapy in a population with high unmet need.

The distinct population of endothelial cells that line blood vessels in the insulin-producing “islets” of the human pancreas have been notoriously difficult to study, but Weill Cornell Medicine investigators have now succeeded in comprehensively detailing the unique characteristics of these cells.

The resulting atlas advances basic research on the biology of the pancreas and could lead to new treatment strategies for diabetes and other pancreatic diseases.

In the study, published in Nature Communications, the researchers devised a set of methods for rapidly isolating and profiling endothelial cells called ISECs (islet-specific endothelial cells) from donor pancreases.

Vimentin is a type III intermediate filament (IF) protein normally expressed in cells that develop into connective tissue, blood vessels, and lymphatic tissue (mesenchymal cells). Despite being widely studied, its role in tumor growth and progression remains unexplored.

A team of researchers at Queen Mary University of London have discovered how a small change in the vimentin protein can make breast cancer more aggressive. The work is published in the journal eLife.

By modifying a specific amino acid cysteine to serine residue at position 328 in vimentin, they discovered that this mutation disrupted the protein’s interaction with the cell’s structural network. Remarkably, the mutated vimentin induced aggressive cancer-like behavior in breast cancer cells, including faster cell growth, migration, and invasion accompanied by reduced cell adhesion.

Careful selection of Cas13 variants and delivery methods minimizes collateral RNA degradation.

A joint research team from the LKS Faculty of Medicine (HKUMed) and the Faculty of Science at the University of Hong Kong has uncovered an unexpected interaction between chemotherapeutic agents and a crucial efficacy marker.